From the
Departments of Surgery, ¶Microbiology and Immunology,
Medicine, and ¶¶Biochemistry and Molecular Biology and
the ||Walther Oncology Center, Indiana
University School of Medicine, Indianapolis, Indiana 46202 and the**
Walther Cancer Institute, Indianapolis,
Indiana 46208
Received for publication, January 20, 2003 , and in revised form, March 17, 2003.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The transcription factors that regulate CXCR4 expression in breast cancer cells are currently unknown. We considered the possibility that the extracellular signal-activated transcription factor NF-B is involved in the expression of CXCR4 because NF-
B has been shown to up-regulate the expression of several prometastatic and proangiogenic genes including interleukin 6 (IL-6), IL-8, urokinase-type plasminogen activator (uPA), matrix metalloproteinase 9 (MMP-9), and vascular endothelial growth factor (58). In addition, inhibitors of NF-
B have been shown to reduce metastasis in xenograft models (9). NF-
B is a heterodimeric complex of Rel family proteins that is physically confined to the cytoplasm of normal cells through its interaction with inhibitor of
B (I
B) proteins (6). A heterodimer composed of p50 and p65 subunits is the predominant form of NF-
B, although several other cell type-specific heterodimers have been identified. Upon exposure of cells to growth factors and cytokines such as epidermal growth factor, IL-1, and tumor necrosis factor
, a series of signaling events target I
B for degradation, promoting the nuclear translocation of NF-
B. NF-
B binds to its response elements (5'-GGGPuNNNPyPyCC-3' where Pu is a purine and Py is a pyrimidine) in the promoter region of target genes and activates transcription (5). CXCR4 may be one of the NF-
B target genes as a putative NF-
B binding site (5'-GAGGCATTTCC-3', 230 to 240) is present in the promoter region of CXCR4 (10).
Several laboratories, including ours, have demonstrated constitutive activation of NF-B in a variety of cancers (1117). We have shown that constitutively active NF-
B is responsible for overexpression of prometastatic and antiapoptotic genes in breast cancer cells (14, 1820). In addition, we and others have shown that cancer cell-derived heregulin, IL-1
, and/or overexpression of epidermal growth factor receptor is involved in constitutive NF-
B activation in breast cancer (2124). The present study was initiated to determine whether NF-
B promotes organ-specific metastasis by selectively up-regulating CXCR4. We demonstrate that NF-
B directly regulates the expression of CXCR4, which appears to be critical for the motility of cancer cells in response to SDF-1
in vitro. In addition, we also show that cells that express CXCR4 are clonally selected during their growth in the mammary fat pad of nude mice. A further increase in CXCR4 expression and SDF-1
-mediated migration was observed in cancer cells that metastasized to the lungs.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasmid Constructs and Transient Transfection AssaysThe CXCR4 promoter was recloned by PCR using a Genome Walker kit (Clontech). PCR-amplified DNA was cloned into the pBL-CAT3 vector and sequenced. Deletion mutants were also generated by PCR. The p65, p50, and Bcl-3 expression vectors were a generous gift from Dr. W. Greene (Gladstone Institute for Virology and Immunology, San Francisco, CA). The expression vectors for NIK, IKK, and IKK
were a generous gift from Dr. D. Donner (Indiana University School of Medicine). The CXCR4 expression vector was a kind gift from Dr. G. Alkhatib (Indiana University School of Medicine). MCF-7 and MDA-MB-231 cells were transfected with the CXCR4/CAT reporter and expression vectors along with a
-galactosidase expression vector (RSV
-gal and pcH110 for MCF-7 and MDA-MB-231, respectively) by the calcium phosphate method. The
-galactosidase activity and CAT activity in an equal number of
-galactosidase units were measured as described previously (14).
Electrophoretic Mobility Shift Assay (EMSA)COS-1 cells were transfected with 10 µg of expression vectors, and whole cell extracts or nuclear extracts were prepared 48 h after transfection as described previously (14, 19). EMSA was performed with CXCR4, NF-B, and SP-1 probes as described previously (14).
RNase Protection AssayTotal RNA was prepared using the RNeasy kit (Qiagen). The RNase protection assay with hCR6 or hAPO-5 probes (BD Pharmingen) was performed as described previously (19). The hCR6 probe set simultaneously measures the expression of CXCR1, CXCR2, CXCR3, CXCR4, BLR-1, BLR-2, and V28. The hAPO-5 probe measures XIAP, TRAF-1, TRAF-2, TRAF-3, TRAF-4, cIAP-1, cIAP-2, and TRPM-2.
Mouse Mammary Fat Pad Injection and Isolation of Cancer Cells MDA-MB-231 cells (106) were injected into the mammary fat pad of 7-week-old nude mice. Mammary tumors were resected after 6 weeks, minced, and digested for 1 h at 37 °C in digestion buffer (2 mg/ml collagenase type 3, 1 mg/ml hyaluronidase in 10 ml of PBS/g of tumor). Cell pellets were digested again for 20 min at 37 °C with protease (12.5 mg/ml in PBS). Cell pellets were washed in PBS and plated in growth medium. Metastatic cells from the lungs were similarly isolated with the exception that the lungs were collected 8 weeks after removal of the primary tumor. CXCR4 expression was measured periodically in cultured tumor- and metastasis-derived cancer cells. Data presented in the text were obtained from cells cultured for 1 month.
Cell Surface Expression of CXCR4 Cell surface expression of CXCR4 was measured by flow cytometry. MDA-MB-231 cells were stained with fluorochrome-conjugated monoclonal antibodies to either CXCR4 or an isotype control (BD Pharmingen) in accordance with the manufacturer's specifications and then analyzed by flow cytometry (25). The staining protocol used was as follows. Cells were first washed in PBS, penicillin, streptomycin, 1% bovine serum albumin and resuspended in 100 µl of PBS, penicillin, streptomycin, 1% bovine serum albumin containing the appropriate antibody. Samples were mixed and incubated at 4 °C in the dark for 40 min. The cells were then washed twice in PBS, penicillin, streptomycin, 1% bovine serum albumin and fixed in PBS, 1% paraformaldehyde. One hundred thousand events were accumulated for each analysis. Samples were analyzed in triplicate, and the data were averaged for statistical analysis. Data are presented as means ± S.E., and comparisons were made using the two-tailed Student's t test.
Chemotaxis AssayChemotaxis assays were performed using 96-well chemotaxis chambers (NeuroProbe) in accordance with the manufacturer's instructions as described previously with minor variations (25). In brief, 0, 12.5, 25, 50, 100, 200, 400, or 800 ng/ml CXCL12/SDF-1 was added to 300 µl of phenol red-free RPMI 1640 medium supplemented with 10% fetal bovine serum in the lower chamber. Twenty-five thousand fluorescent-tagged (4 µg/ml calcein AM, Molecular Probes, Eugene, OR) cells in 50 µl of medium were added to the upper chamber, separated from the lower chamber by a membrane (5.7-mm diameter, 5-µm pore size, polycarbonate membrane). Total cell migration was obtained by measuring the fluorescence (excitation, 485 nm; emission, 530 nm) on a microplate spectrofluorometer and calculating the cell number in the lower chamber in comparison to a cell number standard curve after 2 h of incubation at 37 °C in 5% CO2. Percentage of migration was calculated by dividing the number of cells in the lower chamber by the total cell input multiplied by 100 and subtracting random migration (always less than 7%) to the lower chamber in the absence of SDF-1
. Three samples were analyzed separately in triplicate, and the data were averaged for statistical analysis. Data are presented as means ± S.E., and comparisons were made using the two-tailed Student's t test.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
To ensure that there is a correlation between CXCR4 mRNA and cell surface expression of the CXCR4 protein, we performed flow cytometric analysis with an antibody that specifically recognizes CXCR4 on the cell surface. Cell surface expression of CXCR4 was observed in MCF-7 cells that overexpress IL-1 but not in MCF-7-pcDNA3 cells (Fig. 2). Taken together, these results indicate that CXCR4 expression in breast cancer cells is regulated by NF-
B as well as by the cytokines that induce NF-
B.
|
NF-B Directly Regulates the CXCR4 PromoterTo determine whether NF-
B directly regulates CXCR4 promoter activity, we performed a transient transfection assay in MCF-7 breast cancer cells with a CXCR4/CAT reporter. Two reporters, one with the 897 to +7 region (CXCR4(897)/CAT) and the other with the 209 to +7 region (CXCR4(209)/CAT) of the CXCR4 promoter, were used. Reporter activity was measured in the absence or presence of the NF-
B inducers tumor necrosis factor
, IL-1
, or TPA. IL-1
and TPA induced CXCR4/CAT reporter activity (Fig. 3A). Constitutive CXCR4 promoter activity in MDA-MB-231 cells was reduced by I
B
SR (Fig. 3B). Induction of CXCR4(209)/CAT by IL-1
and TPA suggests that induction of CXCR4 by IL-1
and TPA is an indirect effect of NF-
B activation or that the NF-
B binding site in the CXCR4 promoter is distinct from the putative site predicted from the TFSEARCH computer program. To distinguish between these two possibilities, we generated additional deletion mutants (CXCR4(121)/CAT and CXCR4(66)/CAT) and tested them for activity in the presence of various subunits of NF-
B. The p65 but not the p50 subunit of NF-
B increased the activity of both reporters (Fig. 3C). Among the upstream kinases involved in NF-
B activation, NIK activated the CXCR4 promoter. IKK
but not IKK
activated CXCR4(897)/CAT. Although the basal activity of CXCR4(66)/CAT was 5 times lower than that of CXCR4(121)/CAT, the p65 subunit still activated this reporter. These results suggest that the NF-
B response element is located within the 66 to +7 sequence of the CXCR4 promoter.
|
We next determined direct binding of the NF-B subunits to the 66 to +7 region of the CXCR4 promoter by EMSAs using extracts from COS-1 cells transfected with various subunits of NF-
B and the 66 to +7 region of CXCR4 as a probe. The p50 subunit, either alone or in combination with the p65 subunit, bound to the probe (Fig. 4, lanes 14). Similar results were obtained when nuclear extracts instead of whole cell extracts were used (Fig. 4, lanes 57). Neither c-Rel nor Bcl-3 bound to this region (data not shown). Unlabeled oligonucleotide with a classical NF-
B binding site from the immunoglobulin promoter but not the SP-1 binding site reduced the CXCR4 probe·protein complex formation (Fig. 4, lanes 810). The CXCR4 DNA probe·protein complex could be disrupted by an antibody against p65 and supershifted partially by an antibody against p50 (lanes 1114). A nonspecific antibody (against the p110 subunit of phosphatidylinositol 3-kinase) had no effect on the CXCR4 probe·protein complex (lane 14). These results indicate that the p50 and p65 subunits of NF-
B directly bind to the CXCR4 promoter. Because this region of the promoter lacks a classical NF-
B response element, it appears that the p50 and p65 subunits bind to a non-classical response element. The exact p50 and p65 binding site sequence is yet to be determined because results of a DNase I footprinting assay were inconclusive (data not shown). Also we did not detect the binding of NF-
B subunits using EMSA when the probe contained only the 66 to 33 or the 32 to +1 regions of the CXCR4 promoter (data not shown). Thus, it appears that NF-
B DNA binding requires the entire 66 to +1 region.
|
NF-B Regulates SDF-1
-mediated Migration of MDA-MB-231 Cells through CXCR4 To determine the consequence of NF-
B inhibition on SDF-1
-mediated migration of MDA-MB-231 cells, we performed a chemotaxis assay with LXSN11, I
B
SR6, and I
B
SR10 cells with increasing concentrations of SDF-1
. SDF-1
-induced motility was observed with LxSN11 cells but not with I
B
SR6 and I
B
SR10 cells (Fig. 5A). We confirmed the requirement of NF-
B for the SDF-1
-induced migration of MDA-MB-231 cells by performing a chemotaxis assay with cells pretreated with parthenolide. Parthenolide at 5 µM completely inhibits constitutive NF-
B DNA binding activity in these cells (19). Inhibition of SDF-1
-dependent migration was observed with cells pretreated with parthenolide (Fig. 5B).
|
Recent studies indicated that NF-B regulates migration of MDA-MB-231 cells through up-regulation of uPA (27). In that case, the failure of I
B
SR cells and parthenolide-pretreated cells to migrate in response to SDF-1
could be due to reduced uPA instead of CXCR4 expression. To directly prove that reduced SDF-1
-dependent migration of I
B
SR cells is due to lower levels of CXCR4 in these cells, we reintroduced CXCR4 by transient transfection and performed a chemotaxis assay. SDF-1
-dependent migration was restored in I
B
SR6 and I
B
10 cells upon reintroduction of CXCR4 cDNA (Fig. 5C). These results confirm that NF-
B is directly involved in SDF-1
-mediated migration of breast cancer cells.
MDA-MB-231 Cells Selected after Growth in Nude Mice Express Higher Levels of Cell Surface CXCR4 Although a major function of SDF-1 is to transiently up-regulate the expression of integrins involved in the binding of CXCR4-expressing cells to the endothelium and egression from the circulation, SDF-1
is also known to activate other growth-promoting signaling pathways (28, 29). If that is the case, unlike in cell culture models, cancer cells that express CXCR4 should grow well in a xenograft model as these cells can take advantage of circulating SDF-1
. Because flow cytometry with an antibody against CXCR4 revealed that less than 10% of MDA-MB-231 cells grown in culture express CXCR4 on their surface, our hypothesis was that only those cells that express higher levels of CXCR4 should grow in nude mice. Furthermore cells expressing CXCR4 should metastasize to organs that express SDF-1
, such as the lungs. To test this possibility, we implanted MDA-MB-231 cells into the mammary fat pad of nude mice, resected the tumors after 6 weeks, and allowed the cancer cells isolated from the tumor to grow in culture. After an additional 8 weeks, cells from the lungs of these mice were cultured. MDA-MB-231 cells isolated after their growth in the mammary fat pad (named TMD231 hereafter) or those that metastasized to the lungs (hereafter called LMD231) expressed very high levels of CXCR4 compared with parental cells grown in culture (Fig. 6, AC). In fact, the highest CXCR4 expression was seen in lung metastatic cells. Increased cell surface expression of CXCR4 in tumor- or lung-derived cells were maintained even after 3 months of growth in culture, which suggests that there is clonal selection of CXCR4-expressing cancer cells in the mammary fat pad. TMD231 and LMD231 cells are free of contaminating mouse cells as indicated by cell surface expression of the epithelial cell-specific antigen (Fig. 6, DF, ESA). Both TMD231 and LMD231 cells showed enhanced SDF-1
-mediated migration compared with cells grown in culture (Fig. 6G). CXCR4 mRNA levels were increased in TMD231 and LMD231 cells compared with MDA-MB-231 cells as determined by an RNase protection assay using a human-specific CXCR4 probe (Fig. 7A). All three cell types expressed similar levels of XIAP, TRAF-3, and TRAF-4 transcripts, which suggests that there is no global increase in transcription in LMD231 and TMD231 cells compared with parental cells (Fig. 7B). Thus, it appears that cancer cells that express CXCR4 on their surface are selected during growth in the mammary fat pad, which could help cancer cells to respond to SDF-1
-mediated growth as well as migration signals. In addition, these CXCR4-expressing cells have a higher potential to metastasize to the lungs.
|
|
We next examined whether inhibitors of NF-B can reduce CXCR4 expression in LMD231 cells. Cells were incubated with either parthenolide (5 µM) or MG132 (10 µM), a proteosomal inhibitor that inhibits NF-
B activation by reducing I
B
, for 4 or 8 h. Parthenolide inhibited CXCR4 expression by
50%, whereas MG132 reduced CXCR4 expression by
80% after 8 h of treatment (Fig. 7C). Thus, NF-
B inhibitors have the potential to reduce growth and survival of cancer cells at metastatic sites through inhibition of CXCR4 expression.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Vascular endothelial growth factor has been shown to induce CXCR4 in breast cancer cells (31). Because vascular endothelial growth factor is a NF-B-inducible gene (32), it is possible that the regulation of CXCR4 by NF-
B may be indirect in some cell types. However, vascular endothelial growth factor may not be responsible for the increased expression of CXCR4 in IL-1
-overexpressing MCF-7 cells as both parental and IL-1
-overexpressing cells contained similar levels of vascular endothelial growth factor transcripts (data not shown). Because both MCF-7 and MDA-MB-231 cells do not express IL-8 receptors CXCR1/2, IL-8 is less likely to be involved in CXCR4 expression (data not shown, also the riboprobe used in Fig. 7 measures CXCR1/2). Taken together, our results as well as published results by others (31, 32) suggest both direct and indirect regulation of CXCR4 expression by NF-
B in breast cancer cells.
Most of the current work on breast cancer metastasis focuses on the role of MMPs and the uPA/uPA receptor/plasminogen network (33, 34). It is believed that the uPA/uPA receptor/plasminogen network activates pro-MMP-1, -MMP-3, -MMP-9, and -MMP-13 produced by stromal cells. Activated MMPs break down the physical barriers of metastasis, thus promoting invasion, intravasation, and extravasation of cancer cells (33, 34). In addition, MMPs promote the growth of cancer cells at both primary and metastatic sites. We and others have shown that the expression of uPA and MMPs in cancer and stromal cells is regulated by NF-B (8, 18). The present report adds CXCR4 to the list of prometastatic genes under the control of NF-
B. Thus, inhibitors of NF-
B should reduce breast cancer metastasis by reducing the expression of a number of prometastatic genes. NF-
B inhibitors should also reduce metastasis of other cancers as several cancers including melanoma, ovarian, prostate, brain, and pancreatic cancers are dependent on CXCR4 for migration, survival, and/or metastasis (3, 3538). This also provides an explanation for the therapeutic benefits observed in patients treated with PS341, a proteosome inhibitor with anti-NF-
B properties (39).
Major observations in our present study are that cancer cells expressing CXCR4 are clonally selected during growth in the mammary fat pad of nude mice and that there is a further increase in CXCR4 expression in cancer cells that metastasize to the lungs. Because elevated CXCR4 expression was maintained in TMD231 and LMD231 cells even after 3 months in culture, it is less likely that the tumor microenvironment played any role in the transcriptional up-regulation of CXCR4. Thus, we believe that there is a clonal selection of CXCR4-expressing cells, which needs to be further verified by immunohistochemistry within the context of the primary tumor and the metastatic sites. However, we feel that that is beyond the scope of the current investigation because of the technical difficulties involved in such analysis. For example, the tumor microenvironment may contribute to the transient expression of CXCR4 in cells that are not clonally selected for metastasis.
Why CXCR4 expression is advantageous to cancer cells remains to be determined. The SDF-1/CXCR4 activated signaling pathways may provide a growth advantage to cancer cells at both the primary and metastatic sites. SDF-1
has been shown to enhance tyrosine phosphorylation and association of components of the focal adhesion complex (28). In addition, it induces phosphatidylinositol 3-kinase and p44/42 mitogen-activated protein kinases but not stress-induced kinases such as p38 kinase and c-Jun amino-terminal kinase (29, 40). The AKT/PKB pathway, activated by phosphatidylinositol 3-kinase, protects a variety of cell types against cytokine-, stress-, and chemotherapy-induced apoptosis (41). Thus, it is possible that cancer cells with cell surface CXCR4 are better equipped to protect themselves from host cytokineas well as chemotherapy-induced apoptosis. The mitogen-activated protein kinase pathway may provide proliferation signals for the cancer cells that express CXCR4 to grow out in the tumor microenvironment. SDF-1
/CXCR4 ligation-induced phosphatidylinositol 3-kinase along with uPA may promote the migration of these cells from the primary site. Taken together, our results reveal multiple functions of NF-
B in the growth, migration, and organ-specific metastasis of breast cancer cells, which in part appear to be mediated through the induction of CXCR4.
![]() |
FOOTNOTES |
---|
Both authors contributed equally to this work.
Supported by National Institutes of Health T32 Training Program Grant DK07519 (to H. E. B.).
|||| To whom correspondence should be addressed: R4-202 Indiana Cancer Research Inst., 1044 W. Walnut St., Indianapolis, IN 46202. Tel.: 317-278-2238; Fax: 317-274-0396; E-mail: hnakshat{at}iupui.edu.
1 The abbreviations used are: SDF-1, stromal derived factor-1
; CXCR, CXC chemokine receptor; NF-
B, nuclear factor-
B; I
B, inhibitor of
B; I
B
SR, I
B
super-repressor; IL, interleukin; EMSA, electrophoretic mobility shift assay; uPA, urokinase-type plasminogen activator; MMP, matrix metalloproteinase; IKK, I
B kinase complex; NIK, NF-
B-inducing kinase; CAT, chloramphenicol acetyltransferase; RSV, Rous sarcoma virus;
-gal,
-galactosidase; XIAP, X-linked inhibitor of apoptosis protein; TRAF, tumor necrosis factor receptor-associated factor; cIAP, cellular inhibitor of apoptosis protein; TRPM-2, testosterone-repressed prostatic message-2; SP-1, specificity protein-1; BLR, Burkitt's lymphoma receptor; PBS, phosphate-buffered saline; TPA, 12-O-tetradecanoylphorbol-13-acetate.
2 S. Kumar, K. D. Miller, H. L. Chua, H. Kishimoto, R. M. Bigsby, and H. Nakshatri, submitted.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|